-

Professor Yehui Shi: The Epigenetic Regulation of HR+ Metastatic Breast Cancer—A Review of the Development Path of HDACi Entinostat
Histone deacetylases (HDACs) are overexpressed in various tumors and are closely related to tumor progression and drug resistance. In hormone receptor-positive (HR+) breast cancer, HDAC overexpression leads to resistance to endocrine therapy and CDK4/6 inhibitors. The targeted application of HDAC inhibitors (HDACi) can effectively block this process, bringing better prognosis to patients. Entinostat, introduced in…
-

World Breast Cancer Awareness Month | Renowned Physicians’ Protection, Building a Healthy Future Together —— Focusing on Breast Cancer Prevention and Treatment (2)
Breast cancer is one of the most common malignant tumors in women and is often referred to as the “pink killer,” posing a serious threat to women’s health. The World Health Organization has designated October as “World Breast Cancer Awareness Month” (also known as Pink Ribbon Month) to raise women’s awareness of breast cancer prevention.…
-

World Breast Cancer Awareness Month | Renowned Physicians’ Protection, Building a Healthy Future Together —— Focusing on Breast Cancer Prevention and Treatment (1)
Breast cancer is one of the most common malignant tumors in women and is often referred to as the “pink killer,” posing a serious threat to women’s health. The World Health Organization has designated October as “World Breast Cancer Awareness Month” (also known as Pink Ribbon Month) to raise women’s awareness of breast cancer prevention.…
-

Global Trends in HBV-Related Liver Cancer: A Growing Concern
Published on February 11, 2025, in Hepatology, this study sheds light on the persistent global burden of hepatitis B virus (HBV)-related liver cancer. While significant progress has been made in…
-

SABCS 2024 | Prof. Charles Geyer: NSABP B-59—Atezolizumab in Neoadjuvant Triple-Negative Breast Cancer
Oncology Frontier: Please share the key findings of the NSABP B-59/GBG-96-GeparDouze study. In particular, what are the highlights regarding the efficacy and safety of atezolizumab when added to neoadjuvant chemotherapy…
-

SABCS 2024 | Professor Janice Tsang: Looking Back at 2024, Sharing Highlight Studies and Insights in Early-Stage Breast Cancer
Oncology Frontier:You introduced “Early Breast Cancer Updates” in Year in Review session. Please review the lecture and tell us about the research progress in the field of early breast cancer…
-

SABCS 2024 | Prof. Luke Peppone: Advancing Pharmacotherapy for Chemotherapy-Induced Nausea From Prochlorperazine to Olanzapine
Oncology Frontier:Could you tell us about the original intention of conducting this URCC 16070 phase III randomized controlled trial? Why choose olanzapine and prochlorperazine as agents for nausea caused by…
-

SABCS 2024 | Professor Michael Gnant: Focusing on Breast Cancer, Interpreting New Developments and Future Trends
Oncology Frontier: You and Professor Zhimin Shao jointly presided over the General Session 2 of this conference. As the moderator of this session, could you please give us an overview…